Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1196  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,957 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

  In this Article
 »  Abstract
 » Introduction
 »  Materials and Me...
 » Results
 » Discussion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded174    
    Comments [Add]    
    Cited by others 14    

Recommend this journal


Table of Contents    
Year : 2014  |  Volume : 62  |  Issue : 1  |  Page : 19-25

Central nervous system lymphoma: Patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield

1 Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
2 Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
3 Department of Neuroimaging and Interventional Radiology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India
4 Department of Neurosurgery, Vikram Hospital, Bengaluru, Karnataka, India

Date of Submission03-Dec-2013
Date of Decision07-Jan-2014
Date of Acceptance26-Jan-2014
Date of Web Publication7-Mar-2014

Correspondence Address:
A Arivazhagan
Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.128272

Rights and Permissions

 » Abstract 

Background: Epidemiology of primary central nervous system lymphoma (PCNSL) world-wide shows an increase in incidence linked to human immunodeficiency virus (HIV) pandemic. Materials and Methods: This retrospective review of case records analyzed the trends of hospital-based incidence of PCNSL over two decades (1991-2010), relation to immune status and effect of steroids on yield of stereotactic biopsy (STB). Results: A total of 76 cases of PCNSL were diagnosed over a period of two decades. Incidence of lymphomas amongst all biopsied lesions showed a gradual increase from 0.18% at the beginning of study period to 0.41% at the end of study period. Only 8.6% (3 of 35 tested) of the PCNSL patients were positive for HIV. The mean age of patients with HIV infection (31.3 ± 3.5 years) was significantly lower compared with those without HIV infection (44.7 ± 10.9 years) (P = 0.033). Diagnosis was obtained by open biopsy in 32 patients (42.1%) and STB in 44 patients (57.9%). Open biopsy yielded a histological confirmation of PCNSL in all cases. Among those who underwent STB, the incidence of negative biopsy with short duration of steroids (≤1 week) was 33.3% and increased to 57.1% with increasing duration of steroid treatment (>1 week). Conclusions: This study documented an increase in hospital based incidence of PCNSL in our institute, independent of HIV association. Steroid intake administration for more than a week prior to biopsy adversely affected the yield of STB in PCNSL.

Keywords: Central nervous system lymphoma, human immunodeficiency virus, incidence, stereotactic biopsy, steroids

How to cite this article:
Manoj N, Arivazhagan A, Mahadevan A, Bhat DI, Arvinda H R, Devi B I, Sampath S, Chandramouli B A. Central nervous system lymphoma: Patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield. Neurol India 2014;62:19-25

How to cite this URL:
Manoj N, Arivazhagan A, Mahadevan A, Bhat DI, Arvinda H R, Devi B I, Sampath S, Chandramouli B A. Central nervous system lymphoma: Patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield. Neurol India [serial online] 2014 [cited 2023 Jan 28];62:19-25. Available from: https://www.neurologyindia.com/text.asp?2014/62/1/19/128272

 » Introduction Top

Lymphomas of central nervous system (CNS) are rare tumors accounting for 3.1% of all primary brain tumors and 2-3% of non-Hodgkin's lymphomas. They may be either secondary to systemic lymphoma or primary without the evidence of systemic involvement. Since secondary spread of systemic lymphoma to CNS occurs late in the course of disease and is a relatively rare event in the absence of primary disease, almost all cases presenting initially with CNS involvement are considered primary central nervous system lymphomas (PCNSL). [1]

Epidemiology of PCNSL world-wide shows a progressive increase in incidence followed by stabilization in the last three decades. [1],[2] This increasing incidence was partially linked to the human immunodeficiency virus (HIV) pandemic. The persistent increase among the immunocompetent however, cannot be rationalized and it remains unresolved whether this increasing incidence is a global phenomenon or is geographically limited. Intriguingly, CNS lymphomas in the Indian population seem to differ in epidemiology and clinical presentation from Western population. For instance, increasing incidence of CNS lymphoma in immunocompromised host has not been seen in Indian studies. [3],[4] The trend in hospital-based incidence, association with immunocompromised state, histological subtypes of PCNSL in Indian population and modalities of diagnosis and management needs further evaluation in Indian scenario as published studies from India are few and are restricted to few case series and reviews. [3],[4],[5],[6],[7],[8],[9] The present study was proposed to analyze the trends of hospital-based incidence of PCNSL over two decades, the diversity of clinical symptomatology, relation to immune status and histopathological characteristics.

 » Materials and Methods Top

This retrospective study included all cases of PCNSL diagnosed histopathologically between 1991 and 2010 in our institute, a tertiary care neurosurgical center in South India. The slides were reviewed by the neuropathologist for confirmation of diagnosis. Cases not consistent with lymphoma on review, secondary CNS lymphoma, or with inadequate tissue to permit immunohistochemical characterization were excluded. The clinical and radiological data were obtained from the case records and radiology archives. All the patients were referred to an oncology center following tissue diagnosis for adjuvant therapy and received chemotherapy based on cyclophosphamide, Adriamycin, vincristine and prednisolone (CHOP) or rituximab added to CHOP (R-CHOP) regimen for PCNSL. They were further followed-up by the medical oncologists in an oncology center.


All sections were stained for routine hematoxylin-eosin stains. Immunophenotyping of tumor cells was carried out by indirect immunohistochemistry for T cell (CD3, monoclonal, 1:50, Biogenex, USA), B cell (CD20, monoclonal, 1:50, Biogenex, USA) and macrophage (CD68, monoclonal, 1:100, Biogenex, USA) markers on serial sections. Additional markers like glial fibrillary acidic protein (monoclonal, 1:100, Novocastra Labs, USA) were employed where essential. The morphological phenotype (centroblastic/immunoblastic) on routine stains and immunophenotype (B cell/T cell) were ascertained. Tissue response as in tumor necrosis, macrophage infiltration of tumor and reactive astrocytic response in adjacent infiltrated host parenchyma were noted.

The clinical, histopathological and radiological features of all the patients, influence of HIV status were analyzed. SPSS 15.0 for Windows (SPSS Inc., USA) was used for statistical analysis and appropriate tests were applied to determine significance.

 » Results Top

Totally 76 cases of PCNSL were diagnosed during the study period of two decades (1991-2010). A progressive increase in the hospital-based incidence of CNS lymphoma was noted during the study period, with a gradual increase from 0.18% of all biopsied lesions at the beginning of the study period to 0.41% at the end [Figure 1]b and c. Males were predominant (76.3%) among the cohort. The age at presentation ranged from 18 to 75 years (mean: 46.80 ± 13.23 years). Most patients were in 5 th and 6 th decade [Figure 1]a. The median duration of clinical symptoms at presentation was 1.5 months (range: 3 days-2 years). The clinical features at presentation are given in detail in [Table 1]. Headache was the most common symptom (68.4%), followed by features of raised intracranial pressure (47/76, 61.8%). Hemiplegia/hemi paresis (44.7%), vomiting (43.4%), cognitive decline (39.5%) and seizures (22.4%) were the other common symptoms at presentation. Cognitive decline was reported as a symptom in only 30 (39.4%) patients, whereas incidence of cognitive decline was much higher on formal testing (40/76, 52.6%). Systemic symptoms such as generalized weakness, fever, weight loss etc., were seen in 14 (18.4%) patients. The cranial nerves most commonly affected were cranial nerve III (n = 5), VI (n = 1) and VII (n = 3).
Figure 1: (a) Shows year wise incidence of central nervous system (CNS) lymphoma in the present series (number of cases in Y axis). (b) Shows age group distribution of cases of CNS lymphoma. (c) Shows the graph of percentage of CNS lymphoma cases among the total biopsies for the study period (percentage depicted in Y axis)

Click here to view
Table 1: Symptoms on presentation (n=76)

Click here to view

Neuroimaging data was available in 72 patients [Figure 2]. On computed tomography/magnetic resonance imaging (MRI), 44 (61.1%) patients had a single lesion and 28 (38.9%) patients had multiple lesions. Lesions were located mainly in the periventricular regions (n = 23; 31.9%), lobar subcortical (n = 20, 27.7%), involving both periventricular and lobar regions (n = 24, 33.3%) or posterior fossa (n = 5, 6.9%). The most frequent pattern of enhancement on gadolinium administration was a homogenous enhancement (62.5%), followed by heterogeneous (25%), patchy (6.9%) and ring (4.2%) enhancement. The lesion was non-enhancing in one case. Most lesions had moderate perilesional edema.
Figure 2: (a and b) T2 Flair axial and T1 post contrast coronal magnetic resonance imaging (MRI) of a patient showed a lesion involving left basal ganglia and brainstem and heterogeneous enhancement. Two smaller lesions, one in the brainstem, separate from the fi rst lesion and another small lesion involving the left temporal lobe were present. The
patient underwent stereotactic biopsy (STB). (c and d) T1 post contrast axial and coronal MRI brain of a 20-year-old male, showed a peripherally enhancing lesion involving corpus callosum and both frontal lobes with severe perilesional edema. Patient underwent STB which yielded a diagnosis of lymphoma

Click here to view

Mode of biopsy

The tissue diagnosis was obtained by open biopsy in 32 (42.1%) patients and stereotactic biopsy (STB) in 44 (57.9%) patients. On analyzing factors influencing the decision for mode of biopsy, presentation with altered sensorium was the most frequent factor favoring open surgery, though not statistically significant (P = 0.586). Lobar location also prompted decision for open biopsy (P = 0.001) compared with periventricular location of lesions. Further, higher proportion of patients (37/57, 64.9%) underwent STB during 2001-2010 when compared with the period between 1991 and 2000 (7/19; 36.8%), which was statistically significant (P = 0.032) [Table 2]. This was due to advances in imaging allowing more precise recognition of lymphoma and easier access to stereotactic biopsies, thereby avoiding craniotomy and major microsurgical procedures.
Table 2: Year of biopsy versus method

Click here to view

Influence of steroids on biopsy yield

History of steroid treatment prior to biopsy was available in 72 of 76 patients. Forty-five (63.8%) patients did not receive any steroids, 17 (23.8%) patients received steroids for <1 week prior to surgery and 9 (12.5%) patients received steroids for >1 week prior to surgery.

All patients who underwent open biopsy (n = 32) had histological confirmation of PCNSL. Of the 42 patients who underwent STB for tissue diagnosis, five were inconclusive. Of these five, four had received steroid treatment for >1 week prior to biopsy. The pre-procedural imaging diagnosis in these four patients was demyelination (n = 2), acute demyelinating encephalomyelitis (n = 1). In one patient who was evaluated and treated at another center, the initial diagnosis was not known. In all these patients, the initial STB was inconclusive. All the patients demonstrated clinical improvement with steroids and were followed-up clinically and radiologically. Two patients had complete radiological resolution and two patients had reduction in size of the lesions at 1 month follow-up. One patient with posterior fossa lesion had increase in size of lesion, for which he underwent open surgery, which confirmed lymphoma. In patients with good response to steroids (n = 4), the lesion recurred after a mean duration of 5.75 months (range: 2-10 months). On reappearance of lesions, these patients underwent repeat STB which yielded a confirmatory diagnosis of CNS lymphoma.

Steroid use prior to surgery was divided arbitrarily into short duration (≤1 week) and long duration (>1 week). An attempt was made to analyze the effect of duration of steroid treatment on diagnostic yield [Table 3]. Of the nine patients with steroid use for long duration, two underwent open biopsy which yielded a diagnosis. The remaining seven patients underwent a STB, in whom four had a non-diagnostic initial STB (P < 0.001). Among 17 patients who received short duration steroids before biopsy, 14 had undergone open biopsy which yielded a confirmatory diagnosis. Biopsy was inconclusive in one out of the three patients who underwent STB. We noted that open biopsy yielded a confirmatory diagnosis, irrespective of steroid intake and duration of steroid treatment [Table 3]. Interestingly, a short duration of steroid intake demonstrated a trend toward inconclusive STB when compared with those who were not started on steroids (P = 0.086), while long duration of steroid intake had significant influence on diagnostic yield of STB (P < 0.001). The incidence of negative STB with short duration of steroids was 33.3%, which increased to 57.1% with a long duration of steroid treatment.
Table 3: Steroid treatment versus non-diagnostic biopsy

Click here to view

CNS lymphoma and HIV serology

HIV serology status was available for 35 patients among the total cohort. Many patients, especially in early part of the study period, were not tested for HIV status. Of the 35 cases tested, only 3 (8.6%) were positive. Among HIV negative patients, one had a low CD4 count (221/μL). No other cause for immunocompromised state such as post-transplant state, history to suggest congenital immunodeficiency states or long-term steroid usage was identified in any other patients.

We noted that the mean age of patients with HIV (31.3 ± 3.5 years) was significantly lower compared with patients without HIV (44.7 ± 10.9 years) (P = 0.033). Among the HIV positive patients, two presented with seizures and one patient presented with hemi paresis. The duration of symptoms was short in two patients (<1 month), while one had seizures for 1 year before he underwent evaluation. Imaging available in only two of these patients, revealed uniformly enhancing lesions with moderate perilesional edema. One patient had two lesions, a periventricular and a lobar; while the other had a single periventricular lesion. Diagnosis was obtained by STB (n = 2) and open surgery (n = 1).

Histopathology and immunohistochemistry

Detailed slide review and immunohistochemistry was performed in 69 patients in whom adequate tissue was available. All cases revealed features of a non-Hodgkin's lymphoma that were immunophenotypically diffuse, large B cell in phenotype. Histologically, the tumor was composed of densely cellular fragments of tightly cohesive cells dispersed in sheets. The individual tumor cells had centroblastic or less commonly immnuoblastic morphology [Figure 3]a. Mitotic activity was high with frequent apoptotic figures in presence of necrosis. Characteristic perivascular or angiocentric pattern splaying apart the reticulin framework of blood vessels was seen in almost all tumors [Figure 3]b and c, more common at the infiltrating borders of the tumor and hence more likely to be seen in resection specimens than STB unless the infiltrating margins were sampled. In cerebellar lymphoma, tumor was frequently noted to extend along Virchow Robin spaces as perivascular sleeves, reaching up to the meninges to flood the subarachnoid space.
Figure 3: Histopathology reveals characteristic features of non- Hodgkin's lymphoma with tumor cells having centroblastic morphology (H and E ×Obj, 100) (a) and characteristic angiocentric pattern of arrangement (H and E ×Obj, 40) (b) splaying apart the reticulin fibers (H and E ×Obj, 20) (c). The tumor cells exhibit strong immunolabeling for CD29 (H and E ×Obj, 20) (d). Scattered mature CD3 positive T lymphocytes (e) and CD68 positive macrophages (H and E ×Obj, 20) (f) are interspersed (V-vessel)

Click here to view

Immunophenotyping revealed all cases to be CD20 expressing large B cell in phenotype [Figure 3]d. Admixture of mature CD3 expressing T cells and less frequently macrophages was seen to variable degree in all cases [Figure 3]e and f.

In those who received short duration of steroids prior to biopsy, early apoptotic changes were seen in tumor cells, in addition to macrophage infiltrates [Figure 4]a and b. CD20 immunolabeling was still retained in tumor cells [Figure 4]c Infiltrates of mature T cells were less frequent [Figure 4]d, while astrocytic response was mild and restricted to brain tumor interface [Figure 4]e.
Figure 4: Changes after short duration of steroids before biopsy. Tumor cells showed early apoptotic changes (a), with foamy macrophages (b). Tumor cells showed CD20 labeling (c). Mature T cells infi ltrates were few (d) with mild astrocytic response at brain tumor interface (e). Changes after long duration of steroids: Shrinkage of tumor cells was prominent along tumor periphery (f) with many tangible body macrophages with ingested apoptotic bodies (g). Tumor cells showed patchy loss of CD20 positivity (h) with many mature T cells infi ltrating tumor (i). Glial response is exuberant (j)

Click here to view

In cases who received long duration of steroids, apoptosis was prominent with several tangible body macrophages with ingested apoptotic bodies conferring a Burkitt-like phenotype to sheets of foamy macrophages [Figure 4]f and g with numerous mature T cells infiltrating the tumor in parenchymal and perivascular distribution [Figure 4]i. CD20 immunoreactivity was patchy with several tumor cells appearing to lose immunoreactivity [Figure 4]h while glial response was exuberant [Figure 4]j. No case of T cell lymphoma, anaplastic large cell lymphoma or Hodgkin's lymphoma was seen in this series.

 » Discussion Top

Differences in demographic and clinical presentation of CNS lymphoma have been reported by previously published studies from the Indian subcontinent compared with the Western studies. The current study, one of the largest series from the Indian subcontinent, confirms these findings and also makes some fresh observations. Patients in our population were a decade younger than that reported from Western studies (55 years). [10],[11],[12] Similar observations were made in previous studies from India. [3],[4],[8],[13] Many western studies have noted cognitive decline/behavioral changes as the common presenting symptom of PCNSL with a reported incidence of 73%. [12],[14],[15],[16] However, we noted that only 35% of patients had cognitive decline, which is similar to other Indian studies reporting a lower incidence of 12.5-23% cognitive symptoms. [7],[8] Lack of a formal neuropsychological testing combined with some degree of under reporting by patient's relatives may be the cause for this observed difference.

There was a progressive increase in the hospital-based incidence of CNS lymphoma during the study period. Percentage of lymphomas in all biopsied lesions showed a gradual increase from 0.18% at the beginning of the study period to 0.41% at the end of the study period in our institute. This is similar to the epidemiological trends reported in western studies. [2],[11] Interestingly, previous Indian studies failed to show any significant increase in incidence and opined that the increase in the incidence of CNS lymphomas over the last two decades was not a universal phenomenon. [3],[4] Inability to demonstrate a statistically significant rise may be due to the smaller cohorts compared with western studies.

HIV positive patients carry a 3-9% lifetime risk of developing CNS lymphomas and this risk increases with longevity. [11],[17] HIV positive patients with CNS lymphomas differ in clinical and radiological characteristics and prognosis, from immune competent CNS lymphoma patients. [12],[18] The present study noted that HIV was associated in 8.6% of lymphoma patients. This is in line with the low incidence of association of CNS lymphomas in the HIV infected population in India noted in other Indian studies wherein only 0-8% cases of CNS lymphomas are HIV positive. [3],[5],[7] It reaffirms the observation, that increase in incidence of CNS lymphomas is independent of an increase in number of HIV positive patients in our population. The present study documented that the mean age of lymphoma patients with HIV was significantly less than those without HIV (P = 0.033).

Since surgical decompression does not improve survival in patients with CNS lymphoma, [19] STB is considered the investigation of choice. We noted that more number of patients in our study have undergone STB in the second half, which can be attributed to better MRI imaging and radiological diagnosis and increasingly easier access to guided stereotactic biopsies in cases of diagnostic difficulties. Inconclusive biopsy following steroid treatment in CNS lymphoma is a frequent observation. [20],[21] Reactive gliosis with variable infiltrates of "B" and "T" lymphocytes and macrophages or a complete absence of tumor cell in routine histopathological examination and immunohistochemistry is reported in lymphomas following steroid treatment. [22],[23] Selective toxicity of glucocorticoids to lymphoma cells and resultant rapid shrinkage has been postulated to be the cause of this finding. Choi et al., in their review of four cases of CNS lymphoma, where biopsy following steroid treatment was inconclusive found that molecular genetic methods may be useful in establishing a diagnosis in such cases. [22] Inconclusive biopsy is a known limitation of STB of any intracranial lesion. [24],[25],[26] However, no study has assessed the frequency of negative biopsy following steroid treatment, to the best of our knowledge. The current study documented 88.6% diagnostic rate of STB, close to the accuracy rate reported in other studies. [24],[25],[26] But patients who received steroids for long duration had 57.1% incidence of negative STB which is highly significant. Shorter duration of steroid therapy also resulted in negative biopsy, to a lesser extent (33.3%). We therefore suggest that whenever lymphoma is suspected on pre-operative imaging, steroids should be avoided prior to obtaining a tissue diagnosis as it decreases the diagnostic yield.

B-cell non-Hodgkin lymphomas constitute 92-98% of PCNSL, of which 95% are diffuse large B cell lymphoma (DLBCL). [27],[28] All morphological variants of DLBCL such as ALK positive large B cell lymphoma, anaplastic variant of DLBCL, immunoblastic variant of DLBCL, Microvillous large B cell lymphoma and T cell/histiocyte rich B cell lymphoma may be found in the CNS. [27],[28],[29] However, in the current study, DLBCL was the only subtype.

The present study describes the peculiarities and patterns of CNS lymphoma in Indian population. A progressive increase in hospital-based incidence interestingly in immunocompetent individuals was documented. We identified that steroid treatment for more than a week significantly resulted in a higher rate of negative STB.

 » References Top

1.Lister A, Abrey LE, Sandlund JT. Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program 2002:283-96.  Back to cited text no. 1
2.Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis. Cancer 2002;95:1504-10.  Back to cited text no. 2
3.Sarkar C, Sharma MC, Deb P, Singh R, Santosh V, Shankar SK. Primary central nervous system lymphoma -A hospital based study of incidence and clinicopathological features from India (1980-2003). J Neurooncol 2005;71:199-204.  Back to cited text no. 3
4.Tandon A, Challa S, Shanmugam M, Gopalan S, Paul RT, Digumarthi R. Epstein-Barr virus as a possible etiologic agent in primary central nervous system lymphoma in immunocompetent individuals. Neurol India 2009;57:36-40.  Back to cited text no. 4
[PUBMED]  Medknow Journal  
5.Agarwal PA, Menon S, Smruti BK, Singhal BS. Primary central nervous system lymphoma: A profile of 26 cases from Western India. Neurol India 2009;57:756-63.  Back to cited text no. 5
[PUBMED]  Medknow Journal  
6.Kumari N, Krishnani N, Rawat A, Agarwal V, Lal P. Primary central nervous system lymphoma: Prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgrad Med 2009;55:247-51.  Back to cited text no. 6
[PUBMED]  Medknow Journal  
7.Pasricha S, Gupta A, Gawande J, Trivedi P, Patel D. Primary central nervous system lymphoma: A study of clinicopathological features and trend in western India. Indian J Cancer 2011;48:199-203.  Back to cited text no. 7
[PUBMED]  Medknow Journal  
8.Paul T, Challa S, Tandon A, Panigrahi M, Purohit A. Primary central nervous system lymphomas: Indian experience, and review of literature. Indian J Cancer 2008;45:112-8.  Back to cited text no. 8
[PUBMED]  Medknow Journal  
9.Rao CR, Jain K, Bhatia K, Laksmaiah KC, Shankar SK. Association of primary central nervous system lymphomas with the Epstein-Barr virus. Neurol India 2003;51:237-40.  Back to cited text no. 9
[PUBMED]  Medknow Journal  
10.Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006;24:1281-8.  Back to cited text no. 10
11.Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999;43:199-201.  Back to cited text no. 11
12.Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104.  Back to cited text no. 12
13.Makhdoomi R, Nayil K, Rayees A, Kirmani A, Ramzan A, Khalil MB, et al. Primary CNS lymphoma in immunocompetent: A review of literature and our experience from Kashmir. Turk Neurosurg 2011;21:39-47.  Back to cited text no. 13
14.Braus DF, Schwechheimer K, Müller-Hermelink HK, Schwarzkopf G, Volk B, Mundinger F. Primary cerebral malignant non-Hodgkin′s lymphomas: A retrospective clinical study. J Neurol 1992;239:117-24.  Back to cited text no. 14
15.Hayakawa T, Takakura K, Abe H, Yoshimoto T, Tanaka R, Sugita K, et al. Primary central nervous system lymphoma in Japan -A retrospective, co-operative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994;19:197-215.  Back to cited text no. 15
16.Herrlinger U, Schabet M, Clemens M, Kortmann RD, Petersen D, Will BE, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998;97:257-64.  Back to cited text no. 16
17.Bayraktar S, Bayraktar UD, Ramos JC, Stefanovic A, Lossos IS. Primary CNS lymphoma in HIV positive and negative patients: Comparison of clinical characteristics, outcome and prognostic factors. J Neurooncol 2011;101:257-65.  Back to cited text no. 17
18.Haldorsen IS, Kråkenes J, Goplen AK, Dunlop O, Mella O, Espeland A. AIDS-related primary central nervous system lymphoma: A Norwegian national survey 1989-2003. BMC Cancer 2008;8:225.  Back to cited text no. 18
19.Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg 2000;92:261-6.  Back to cited text no. 19
20.Geppert M, Ostertag CB, Seitz G, Kiessling M. Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol 1990;80:629-34.  Back to cited text no. 20
21.Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: From clinical presentation to diagnosis. J Neurooncol 1999;43:219-26.  Back to cited text no. 21
22.Choi YL, Suh YL, Kim D, Ko YH, Sung CO, Lee JI. Malignant lymphoma of the central nervous system: Difficult histologic diagnosis after glucocorticoid therapy prior to biopsy. Clin Neuropathol 2006;25:29-36.  Back to cited text no. 22
23.Donaghy M. Shrinking cerebral lymphomas with steroids can cause diagnostic confusion. Pract Neurol 2002;2:218-20.  Back to cited text no. 23
24.Aker FV, Hakan T, Karadereler S, Erkan M. Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: Comparison of results of biopsy and resected surgical specimens. Neuropathology 2005;25:207-13.  Back to cited text no. 24
25.Ferreira MP, Ferreira NP, Pereira Filho Ade A, Pereira Filho Gde A, Franciscatto AC. Stereotactic computed tomography-guided brain biopsy: Diagnostic yield based on a series of 170 patients. Surg Neurol 2006;65 Suppl 1:S1:27-1:32.  Back to cited text no. 25
26.Heper AO, Erden E, Savas A, Ceyhan K, Erden I, Akyar S, et al. An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: A prospective clinicopathologic study. Surg Neurol 2005;64 Suppl 2:S82-8.  Back to cited text no. 26
27.Kadoch C, Treseler P, Rubenstein JL. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus 2006;21:E1.  Back to cited text no. 27
28.Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.  Back to cited text no. 28
29.Jaffe ES. The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-31.  Back to cited text no. 29


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India
Shasanka Das, Bhausaheb Bagal, Hasmukh Jain, Lakhan Kashyap, Sekar Anbarasan, Sharma Abhishek, Suresh Bondili, Lingraj Nayak, Jayshree Thorat, Sumeet Mirgh, Anant Gokarn, Sachin Punatar, Sahay Ayushi, Sridhar Epari, Prashant Tembhare, Prakash Shetty, Nehal Khanna, Jayant Goda, Moiyadi Aliasgar, Tejpal Gupta, Manju Sengar, Navin Khattry, Siddhartha Laskar, Hari Menon
Indian Journal of Hematology and Blood Transfusion. 2022;
[Pubmed] | [DOI]
2 Evidence-based expert consensus on the management of primary central nervous system lymphoma in China
Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li, Hong Chen, Dongxiao Zhuang, Jianyong Li, Bin Wang, Tao Jiang, Lanting Lyu, Yuqin Song, Xiaoguang Qiu, Wenbin Li, Song Lin, Xinghu Zhang, Dehong Lu, Junqiang Lei, Yaolong Chen, Ying Mao
Journal of Hematology & Oncology. 2022; 15(1)
[Pubmed] | [DOI]
3 An Update on Neurosurgical Management of Primary CNS Lymphoma in Immunocompetent Patients
Florian Scheichel, Daniel Pinggera, Branko Popadic, Camillo Sherif, Franz Marhold, Christian Franz Freyschlag
Frontiers in Oncology. 2022; 12
[Pubmed] | [DOI]
4 Sentinel lesion and significance of rebiopsy: a case of primary CNS lymphoma
Dominik Drobisz, Petr Skalický, Adam Pavlicko, Radoslav Matej, Katerina Benešová, David Netuka, Robert Rusina
Neurologie pro praxi. 2022; 23(2): 161
[Pubmed] | [DOI]
5 Treatment of primary central nervous system lymphomas
I. V. Cherkashina, M. A. Vernyuk, A. M. Chervontseva, E. E. Gushchina, L. S. Khayrullina, V. V. Lunin, P. A. Zeynalova, A. A. Fedenko
Oncohematology. 2021; 16(2): 10
[Pubmed] | [DOI]
6 Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study
Florian Scheichel, Franz Marhold, Daniel Pinggera, Barbara Kiesel, Tobias Rossmann, Branko Popadic, Adelheid Woehrer, Michael Weber, Melitta Kitzwoegerer, Klaus Geissler, Astrid Dopita, Stefan Oberndorfer, Wolfgang Pfisterer, Christian F. Freyschlag, Georg Widhalm, Karl Ungersboeck, Karl Roessler
BMC Cancer. 2021; 21(1)
[Pubmed] | [DOI]
7 A diagnostic challenge of primary Central nervous system lymphoma: from the eyes to the brain
Min Su, Dehui Huang, Liuqing Sun, Zhao Dong, Lei Wu, Shengyuan Yu
International Journal of Neuroscience. 2021; 131(11): 1139
[Pubmed] | [DOI]
8 Use of fluorescein sodium to obtain histological diagnosis of primary Central nervous system lymphoma ghost tumour despite disappearance on intraoperative magnetic resonance imaging: technical note and review of the literature
Jia Xu Lim, Daniel Loh, Leanne Tan, Lester Lee
British Journal of Neurosurgery. 2020; : 1
[Pubmed] | [DOI]
9 HIV prevalence in primary central nervous system lymphoma: A systematic review and meta-analysis
Raduan Ahmed Franca, Antonio Travaglino, Silvia Varricchio, Daniela Russo, Marco Picardi, Fabrizio Pane, Mirella Pace, Marialaura Del Basso De Caro, Massimo Mascolo
Pathology - Research and Practice. 2020; 216(11): 153192
[Pubmed] | [DOI]
10 Advances and challenges in the treatment of primary central nervous system lymphoma
Hua Yang, Yang Xun, Anping Yang, Fang Liu, Hua You
Journal of Cellular Physiology. 2020; 235(12): 9143
[Pubmed] | [DOI]
11 Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India
Bishan Dass Radotra, Mayur Parkhi, Debajyoti Chatterjee, Budhi Singh Yadav, Nagarjun Rao Ballari, Gaurav Prakash, Sunil Kumar Gupta
Surgical Neurology International. 2020; 11: 424
[Pubmed] | [DOI]
12 Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences
Mukesh Patekar, Narayan Adhikari, Ahitagni Biswas, Vinod Raina, Lalit Kumar, Bidhu Kalyan Mohanti, Ajay Gogia, Atul Sharma, Atul Batra, Sameer Bakhshi, Ajay Garg, Sanjay Thulkar, Meher Chand Sharma, Sreenivas Vishnubhatla, Saphalta Baghmar, Ranjit Kumar Sahoo
Journal of Global Oncology. 2019; (5): 1
[Pubmed] | [DOI]
13 Diagnostic Evaluation in Primary CNS Lymphoma
Rimas V. Lukas,Peter Riedell,Peleg M. Horowitz,Peter Pytel,David O. Kamson
The Neurologist. 2018; 23(2): 53
[Pubmed] | [DOI]
14 Case of 55-year-old female with primary central nervous system lymphoma, presenting with brain and eye lesions and long-term relapsing/remitting course
Takuya Sasaki,Takahiro Nakayama,Mizuki Kitamura,Yukio Kakuta,Ichiro Imafuku
Rinsho Shinkeigaku. 2015; 55(8): 567
[Pubmed] | [DOI]


Print this article  Email this article
Online since 20th March '04
Published by Wolters Kluwer - Medknow